In conclusion, BARI-STEP, a randomized, placebo-controlled trial investigating the use of once-weekly semaglutide 2.4 mg in a post-bariatric patient population with a suboptimal clinical response, demonstrates that semaglutide 2.4 mg in patients with a suboptimal clinical response results in substantial, clinically relevant body weight reduction, and improvements in metabolic health and quality of life
However, no controlled conditions (placebo effects, natural healing, concurrent treatments confound results)
Enrolled participants receive the study medication for free along with regular medical monitoring
Mounjaro is approved as a treatment for type 2 diabetes, while Zepbound is authorized as a treatment for obesity as well as sleep apnea
Orforglipron , an oral GLP-1 agonist, has shown the ability to maintain weight loss in patients switching from injectable therapies
b , FSC curves of the final refined model versus the final cryo-EM map (full dataset, black), of the outcome of model refinement with a half map versus the same map (red), and of the outcome of model refinement with a half map versus the other half map (green)
